The approval allows for the release of an optional upgrade to the Aspire Cristalle digital mammography system.
Here’s what you should know.
1. The upgrade increases the machine’s diagnostic accuracy while also lowering recall rates for non-cancer cases.
2. The option upgrade is now available in the United States. It has been widely in available across Europe, Asia and Latin America since May 2013.
3. Rob Fabrizio, director of strategic marketing, digital radiography and women’s health at FUJIFILM Medical Systems U.S.A, said, “Receiving FDA approval for DBT is a momentous occasion for Fujifilm. The unique dose savings and patient comfort innovations already available in the ASPIRE Cristalle FFDM system are now coupled with the new 3-D imaging capabilities – an exciting advancement that U.S. providers have long been waiting for in their fight for early detection of breast cancer.”
More articles on healthcare:
St. Mary’s Hospital opens orthopedic-driven ASC: 4 notes
Surgery Partners opens ophthalmology-driven ASC — 3 highlights
Christ Hospital’s dispute with St. Elizabeth Healthcare over $24M ASC may wage on for years
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.